Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 10, 2024 | clinicaltrials |
| NCT05364645 | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05690035 | Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05738161 | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma(MACOCUC-01) | withdrawn | Phase 1 | 0 | Insel Gruppe AG, University Hospital BernOTHER | 0 | Jul 5, 2024 | clinicaltrials |
| NCT05869994 | Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures | withdrawn | — | 0 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05204160 | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05408195 | E-Care Acceptability for Older People Undergoing Chemotherapy(ONCO-CHATBOT) | withdrawn | N/A | 0 | University Hospital, ToulouseOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT05545969 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma(Neo PeLeMM) | withdrawn | Phase 2 | 0 | Melanoma Institute AustraliaOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04833959 | Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | withdrawn | Phase 1 | 0 | Stanford UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05740449 | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART A) | withdrawn | Phase 1 / Phase 2 | 0 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT02840227 | The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections | withdrawn | N/A | 0 | The Cleveland ClinicOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05567055 | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations | withdrawn | Phase 2 | 0 | Timothy Burns, MD, PHDOTHER | 0 | Jun 17, 2024 | clinicaltrials |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | withdrawn | Phase 2 | 0 | Northside Hospital, Inc.OTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | withdrawn | N/A | 0 | Medical University of GrazOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05572476 | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer(LURBIMUNE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT05309018 | Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML(LAMIPA) | withdrawn | — | 0 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT02407613 | Efficacy of MR-HIFU Ablation of Breast Cancer | withdrawn | N/A | 0 | UMC UtrechtOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05411107 | Oral Iloprost for the Prevention of Lung Cancer In Former Smokers | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | withdrawn | N/A | 0 | The University of Tennessee, KnoxvilleOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT03122249 | Oncology Associated Symptoms & Individualized Strategies(OASIS) | withdrawn | N/A | 0 | Stephanie Gilbertson-WhiteOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05359042 | Electronic Patient Reported Outcomes in Patients With Gastrointestinal Cancers | withdrawn | N/A | 0 | University of California, San FranciscoOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT01622764 | 89Zr-RO5323441 PET Imaging in Glioblastoma | withdrawn | Phase 2 | 0 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05073172 | StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients | withdrawn | N/A | 0 | OHSU Knight Cancer InstituteOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05403580 | Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | withdrawn | Phase 3 | 0 | Mayo ClinicOTHER | 0 | May 6, 2024 | clinicaltrials |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 6, 2024 | clinicaltrials |
| NCT03035357 | Neoadjuvant Listeria or Daratumumab in Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 3, 2024 | clinicaltrials |
| NCT03044795 | Response to PARP Inhibitor Predicted by the RAD51 Assay(REPAIR) | withdrawn | Phase 2 | 0 | University Medical Center GroningenOTHER | 0 | May 3, 2024 | clinicaltrials |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | May 2, 2024 | clinicaltrials |
| NCT05950113 | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer | withdrawn | Phase 2 | 0 | GenmabINDUSTRY | 6 | Apr 30, 2024 | clinicaltrials |
| NCT04614766 | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors(SPORE-3) | withdrawn | Phase 1 / Phase 2 | 0 | David BushnellOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | withdrawn | Phase 1 / Phase 2 | 0 | Indiana UniversityOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05900648 | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT04685525 | Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04542603 | Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT04995536 | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT06331585 | Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy | withdrawn | Phase 2 | 0 | Hetian District People's HospitalOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial | withdrawn | Phase 3 | 0 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT04272268 | Feasibility and Safety of Using Nasal High Flow Oxygen Postoperatively to Reduce Respiratory Complications(Hi-FLO) | withdrawn | — | 0 | University Hospitals of North Midlands NHS TrustOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05356585 | Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer | withdrawn | — | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05894447 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers | withdrawn | Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 11, 2024 | clinicaltrials |
| NCT05304663 | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression(GLIOASTRA) | withdrawn | Phase 1 | 0 | Philogen S.p.A.INDUSTRY | 0 | Apr 8, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jul 10, 2024source: clinicaltrials